This member-only webinar explores how life sciences organisations can strengthen digital and AI capabilities, access training and funding opportunities, and prepare their workforces for the future.
Q3 UK biotech financing; Budget calls; early-stage funding gap; faster clinical trials; connecting Government and industry; digital and AI skills webinar
Brainomix, today announced a new partnership with the Pulmonary Fibrosis Foundation (PFF) to bring the voices of patients and caregivers into exploring how AI-powered imaging could support the care of people living with pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).
Chris Molloy on the Labour Party conference; female biotech leaders in Edinburgh; Women in Biotech mentoring programme; Advanced Therapy Treatment Centre; BioSolutions Advisory Board; TechBio UK; and careers at BIA
Brainomix, a global leader in AI-powered imaging for stroke and lung disease, today announced that five abstracts showcasing its proprietary biomarkers and advanced CT analysis technologies will be presented at the European Respiratory Society (ERS) Congress 2026, taking place September 5–9 in Barcelona, Spain.
Chris Molloy on mRNA cancer vaccine reaching Phase 3 milestone, Scancell MHRA authorisation, microbiome-based medicinal products, MHRA voucher scheme for SMEs, Scotland and data driver projects
Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology.
The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.
Driven by world-class science and monumental funding, the UK TechBio sector is undergoing a profound paradigm shift – meet the innovative BIA members leading the charge
Cell and Gene Therapy Catapult (CGT Catapult) will provide investment to Lir Therapeutics (Lir) to accelerate the development of nAAVigator, its AI-driven AAV capsid design platform.
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.